PER - Megathread, page-285

What do you see as most desirable for PER, Interested in your thoughts @George.

PARTNERSHIP TIMING

AFTER Trial readout (assuming results repeat ph2a);
- more $ upfront as partner has less risk having seen results
- after fda approval (CR to get there) then damand big bucks
Advantage; could gain massive deal with fda partial approval getting true value upfront ie hundreds of millions

BEFORE Trial readout as per your hunch;
- increase sp and cash position early from a deal to then negotiate from a less needy position for the remaining half? of the world market
Advantage;
- upon release of data results sp may fly higher given CR is not immediately on the horizon
- look at dxb having just 10m upfront they have continued to 6 bag in 6 months thanks to the credibility from this early partnership with CR along the way to further bolster their negotiation power $$ for future licencing deal ie usa and china

thanks